Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;108(1):47-55.
doi: 10.1177/03008916211014954. Epub 2021 May 18.

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

Roberta Minari  1 , Francesco Bonatti  1 , Giulia Mazzaschi  1   2 , Alessandra Dodi  2 , Francesco Facchinetti  1   3 , Francesco Gelsomino  4 , Gloria Cinquegrani  2 , Anna Squadrilli  1 , Paola Bordi  1 , Sebastiano Buti  1 , Melissa Bersanelli  1 , Alessandro Leonetti  1 , Agnese Cosenza  1 , Leonarda Ferri  1 , Elena Rapacchi  1 , Federico Quaini  2 , Andrea Ardizzoni  4 , Marcello Tiseo  1   2
Affiliations

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

Roberta Minari et al. Tumori. 2022 Feb.

Abstract

Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).

Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups.

Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype (p = 0.05).

Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.

Keywords: NSCLC; PD-L1; SNPs; biomarker; immunotherapy.

PubMed Disclaimer

MeSH terms

LinkOut - more resources